December 20th 2024
The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.
December 13th 2024
The partners will aim to establish a platform that enables rapid development of DPI products.
December 7th 2024
LNPs have gained solid ground as a drug delivery system for mRNA due to their success in the vaccines arena.
December 4th 2024
With its new offering, Lonza can tailor services to support smart capsule companies with its bi-layer capsule manufacturing technology.
November 21st 2024
The companies will collaborate to create and test circVec DNA–LNP formulations for use in potential therapeutic applications.